Given the specialist nature of IRT systems, it is now almost impossible for mid and small-sized pharma companies, and biotechs, to develop or maintain bespoke, internally-managed IRT systems. Most company staffing protocols simply don’t allow for the kind of infrastructure necessary to maintain such a specialist team, so we must inevitably look elsewhere for specialist IRT service providers.
What happens when individual study teams are given the responsibility to select and manage their own chosen IRT vendor? How often have we seen one team encountering seemingly insurmountable difficulties, leading any teams following in their footsteps to automatically reject that IRT vendor, select another and subsequently experience very similar problems? How much better could the experience be if we were to invest proper time and effort with a single selected vendor, over time learning from our mistakes, improving our procedures and passing on knowledge to the study teams following behind us?
What are the pitfalls when each team is allowed to select their own IRT vendor?
What does a good IRT vendor partnership look like?
What will we need to invest in order to develop a successful partnership?
How do we choose a partner?
Where could that partnership take us in the future?
The partner companies we work with are critical to our success and never more so than when we select and cooperate with an IRT service provider. With a little careful thought and a positive internal approach our partnerships can be streamlined, efficient and rewarding for both sponsor and IRT vendor alike resulting in better IRT systems, built more speedily, at reduced cost and with a fraction of the customary frustration and duplication of effort.
In this session, you’ll learn:
Appreciating the importance of positive vendor partnerships
Developing a streamlined sponsor/vendor relationship
A modern approach to UAT
Best practices for UAT and beyond
About Our Speaker:
Kate Chapman, the Director of Clinical Technology Consultants Ltd. and the Principal Consultant, Clinical Technology Consultants, Winchester, UK, has 19 years of experience in the Clinical Development area of the Pharmaceutical and Biotechnology sector, with a specialization in IRT. Kate has extensive experience as an end-user of IRT systems and continuously reviews many of the systems that are currently available. She worked with companies like Sandoz, Novartis, Innovex, Roche, Bristol Myers Squibb, Sanofi, Merck, Sharpe and Dohme, Pharmacia, PPD and Emergent Biosciences. Kate most recently formed and led an internal support function dedicated to IRT services and associated disciplines for Shire Pharmaceuticals.